Kathryn M. Schak, MD
- 3Articles
- 27.8KReads
- 2019–2023Active
- 22Collaborators
- 160Citations
About
Kathryn M. Schak, MD, is affiliated with the Department of Psychiatry and Psychology at the Mayo Clinic Depression Center and Mayo Clinic College of Medicine in Rochester, Minnesota. Her publications from 2019 to 2023 focus on treatment-resistant depression, including studies on intravenous ketamine and intranasal esketamine, as well as factors influencing remission rates such as body mass index. She has also contributed research on the effects of maternal perinatal opioid use on neonatal outcomes.
Publications
Ketamine vs Esketamine for TRD
February 1, 2023
BMI and Remission in Depressed Patients Receiving IV Ketamine
November 12, 2019
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.